Intervention Protocol

Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease

  1. Suetonia C Palmer1,
  2. Kushma Nand2,*,
  3. Leny Dwi Nur Hidayati2,
  4. Anna Munasinghe2,
  5. Craig Nelson2,
  6. Mohamed MH Khafaji3,
  7. Giovanni FM Strippoli4,5,6,7,8

Editorial Group: Cochrane Renal Group

Published Online: 13 JUN 2012

DOI: 10.1002/14651858.CD009904

How to Cite

Palmer SC, Nand K, Dwi Nur Hidayati L, Munasinghe A, Nelson C, Khafaji MMH, Strippoli GFM. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD009904. DOI: 10.1002/14651858.CD009904.

Author Information

  1. 1

    University of Otago Christchurch, Department of Medicine, Christchurch, New Zealand

  2. 2

    Western Health, Western Hospital Renal, Footscray, VIC, Australia

  3. 3

    Benowa, Qld, Australia

  4. 4

    The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia

  5. 5

    University of Bari, Department of Emergency and Organ Transplantation, Bari, Italy

  6. 6

    Mario Negri Sud Consortium, Department of Clinical Pharmacology and Epidemiology, Santa Maria Imbaro, Italy

  7. 7

    University of Sydney, Sydney School of Public Health, Sydney, Australia

  8. 8

    Diaverum, Medical-Scientific Office, Lund, Sweden

*Kushma Nand, Western Hospital Renal, Western Health, 180 Gordon Street, Footscray, VIC, 3011, Australia.

Publication History

  1. Publication Status: New
  2. Published Online: 13 JUN 2012




  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

This review aims to look at the benefits and harms of CERA compared with other epoetins (darbepoetin alfa and erythropoietin alfa or beta) or placebo/no treatment for anaemia in individuals with CKD.